

63-07-03

1640
AT-16
3-12-03

Please type a plus sign (+) inside this box → ☐

PTO/SB/21 (08-00)
Approved for use through 10/31/02. OMB 065-004

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Application Number	09/809,638	
	Filing Date	March 14, 2001	
	First Named Inventor	Mary FARIS et al.	
	Group Art Unit	1642	
	Examiner Name	A. Harris	
Total Number Of Pages In This Submission	6	Attorney Docket No.	511582003500

RECEIVED
MAR 11 2003
TECH CENTER 1600/2300

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Assignment Papers (for an Application)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Fee Attached	<input type="checkbox"/> Drawing(s)	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Amendment / Reply	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input type="checkbox"/> After Final	<input type="checkbox"/> Petition	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Affidavits/declarations	<input type="checkbox"/> Petition to Convert to a Provisional Application	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address	<input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return postcard
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Terminal Disclaimer	
<input checked="" type="checkbox"/> Information Disclosure Statement; PTO form 1449; and 34 references (5 on disc and 29 on paper)	<input checked="" type="checkbox"/> CD, Number of CD(s) 1	
<input type="checkbox"/> Certified Copy of Priority Document(s)	Remarks	
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application		
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53		

SIGNATURE OF APPLICANT, ATTORNEY OR AGENT	
Firm or Individual Name	David L. Devernoe Registration No. 50,128
Signature	
Date	March 5, 2003

CERTIFICATE OF MAILING BY "EXPRESS MAIL"	
Express Mail Label No.: EV 042154997 US	Date of Deposit: March 5, 2003
I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.	
 Garee A. Haney	

Burden Hours Statement: This form is estimated to take 0.2 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Box Patent Application, Washington, DC 20231.




PATENT
Docket No. 511582003500

CERTIFICATE OF MAILING BY "EXPRESS MAIL"

Express Mail Label No.: EV 042154997 US

Date of Deposit: March 5, 2003

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 C.F.R. § 1.10 on the date indicated above and is addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231.


Garee A. Haney

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Mary FARIS et al.

Serial No.: 09/809,638

Filing Date: March 14, 2001

For: 125P5C8: A TISSUE SPECIFIC
PROTEIN HIGHLY EXPRESSED IN
VARIOUS CANCERS

Examiner: A. Harris

Group Art Unit: 1642

RECEIVED
MAR 11 2003
TECH CENTER 1600/2900

SUPPLEMENTAL INFORMATION DISCLOSURE
STATEMENT UNDER 37 C.F.R. § 1.97

Assistant Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. Copies of documents Nos. 2-6 are submitted on Cd-R due to their length. The Examiner is requested to make these documents of record.

This Information Disclosure Statement is submitted:

- ☐ With the application; accordingly, no fee or separate requirements are required.
- ☒ Within three months of the application filing date or before mailing of a first Office Action on the merits; accordingly, no fee or separate requirements are required.
- ☐ After receipt of a first Office Action on the merits but before mailing of a final Office Action or Notice of Allowance.
 - ☐ A fee is required. A check in the amount of * is enclosed.
 - ☐ A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee is believed to be due.
- ☐ After mailing of a final Office Action or Notice of Allowance, but before payment of the issue fee.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the amount of * is enclosed.
 - ☐ A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal form (PTO/SB/17) is attached to this submission in duplicate.

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.


The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to

charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 511582003500. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: March 5, 2003

Respectfully submitted,

By: 
David L. Devernoe
Registration No. 50,128

Morrison & Foerster LLP
3811 Valley Centre Drive
Suite 500
San Diego, California 92130-2332
Telephone: (858) 720-7943
Facsimile: (858) 720-5125

Form PTO-1449

INFORMATION DISCLOSURE CITATION IN AN APPLICATION

(Use several sheets if necessary)

Docket Number 511582003500

Application Number 09/809,638

Applicant

Mary FARIS et al.

Filing Date March 14, 2001

Group Art Unit 1645

Mailing Date March 5, 2003

U.S. PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS

Examiner Initials	Ref. No.	Date	Document No.	Country	Class	Subclass	Translation YES NO
	1.	07/1989	GB 2,211,504	Great Britain			
	2.	10/2001	WO 01/75067	WIPO			
	3.	12/2001	WO 01/94629	WIPO			
	4.	02/2002	WO 02/10449	WIPO			
	5.	04/2002	WO 02/26982	WIPO			
	6.	07/2002	WO 02/55700	WIPO			

OTHER DOCUMENTS

(including author, title, Date, Pertinent Pages, Etc.)

Examiner Initials	Ref. No.	Title
	7.	Abdel-Malek, J. Cell Physiol. (1988) 136:247
	8.	Abe and Saito, J. Neurochem. (2001) 76:217-223
	9.	Batra et al., Prostate. (1991) 19:299
	10.	Cell Growth Differ. (2000) 11:279
	11.	Craft et al., Cancer Res. (1999) 59:5030-5036
	12.	Davies et al., Science (2000) 290:2295
	13.	Filetti et al., Eur. J. Endocrinol. (1999) 141:443
	14.	Fu et al., Int. J. Cancer (1992) 52(6):987-990
	15.	Gergely et al., Clin. Diagn. Lab. Manual (1997) 4:70
	16.	Hollo et al., Biochimica et Biophysica Acta (1994) 1191:384
	17.	Hubert et al., Proc. Natl. Acad. Sci. USA (1999) 96(25):14523-14528

RECEIVED
MAR 12 2003
TECH CENTER 1000/2000

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.

Form PTO-1449

Docket Number 511582003500*

Application Number 09/809,638

INFORMATION DISCLOSURE CITATION
IN AN APPLICATION

(Use several sheets if necessary)

Applicant

Mary FARIS et al.

Filing Date March 14, 2001

Group Art Unit 1645

Mailing Date March 5, 2003

- | | |
|-----|--|
| 18. | Ivanov and Ronai, Oncogene (2000) 19:3003 |
| 19. | Janulis et al., J. Biol. Chem. (1999) 274:801 |
| 20. | Krueger et al., Cancer Res. (1999) 59:6010 |
| 21. | Kaighn et al., Invest. Urol. (1979) 17(1):16-23 |
| 22. | Klein et al., Nature Med. (1997) 3:402-408 |
| 23. | Kubota, J. Cell Biochem. (1994) 56(1):4-8 |
| 24. | Leith et al., Blood (1995) 86:2329 |
| 25. | Linsley et al., J. Exp. Med. (1991) 174:561-566 |
| 26. | Morton and Myszk, Methods in Enzymology (1998) 295:268 |
| 27. | Musil et al., J. Biol. Chem. (2000) 275:25207 |
| 28. | Pemberton et al., J. of Histochemistry and Cytochemistry (1997) 45:1697-1706 |
| 29. | Saffran et al., PNAS (2001) 98(5):2658-2663 |
| 30. | Skryma et al., J. Physiol. (2000) 527:71 |
| 31. | Spitzweg et al., Cancer Res. (2000) 60:6526 |
| 32. | Storrie et al., Methods Enzymol. (1990) 182:203-225 |
| 33. | Tazebay et al., Nat. Med. (2000) 6:871 |
| 34. | Welford, Opt. Quant. Elect. (1991) 23:1 |

RECEIVED
MAR 11 2003
TECH CENTER 1000/2000

EXAMINER:

DATE CONSIDERED:

EXAMINER: Initial if citation considered, whether or not the citation conforms with MPEP 609. Draw a line through the citation if not in conformance and not considered. Include a copy of this form with next communication to applicant.